This database contains 384 studies, archived under the term: "Other"
Click here to filter this large number of results.
Effect of Dextromethorphan-Quinidine on Agitation in Patients With Alzheimer Disease Dementia: A Randomized Clinical Trial
Cummings, J. L.,
Lyketsos, C. G.,
Peskind, E. R.,
Porsteinsson, A. P.,
Mintzer, J. E.,
Scharre, D. W.,
De La Gandara, J. E.,
Agronin, M.,
Davis, C. S.,
Nguyen, U.,
Shin, P.,
Tariot, P. N.,
Siffert, J.
IMPORTANCE: Agitation is common among patients with Alzheimer disease; safe, effective treatments are lacking. OBJECTIVE: To assess the efficacy, safety, and tolerability of dextromethorphan hydrobromide-quinidine sulfate for Alzheimer disease-related agitation. DESIGN, SETTING, AND PARTICIPANTS: Phase 2 randomized, multicenter, double-blind, placebo-controlled trial using a sequential parallel comparison design with 2 consecutive 5-week treatment stages conducted August […]
Memantine in moderately-severe-to-severe Alzheimer’s disease: A postmarketing surveillance study
Clerici, Francesca,
Vanacore, Nicola,
Elia, Antonietta,
Spila-Alegiani, Stefania,
Pomati, Simone,
Da Cas, Roberto,
Raschetti, Roberto,
Mariani, Claudio
Background: Postmarketing surveillance studies (PMS) are an important tool for evaluating a drug’s effectiveness and safety in clinical practice. To our knowledge, no PMS on memantine monotherapy for moderately-severe-to-severe Alzheimer’s disease (AD) according to National Institute of Neurological and Communicative Disorders and Stroke—Alzheimer’s Disease and Related Disorders Association criteria has been conducted to date. Objective: […]
Sharing meals with institutionalized people with dementia: A natural experiment
Nutritional deficiency can have dramatic effects on the physical and psychological status of older adults. Although food supplements can enhance nutritional status, several authors suggest that more ecological means could also have beneficial impacts. Therefore, a natural experiment was conducted to study the impact of changed mealtime experiences for people with Alzheimer-type dementia. Two special […]
Efficacy and safety of cerebrolysin in moderate to moderately severe Alzheimer’s disease: Results of a randomized, double‐blind, controlled trial investigating three dosages of cerebrolysin
Alvarez, X. A.,
Cacabelos, R.,
Sampedro, C.,
Aleixandre, M.,
Linares, C.,
Granizo, E.,
Doppler, E.,
Moessler, H.
Background: Cerebrolysin is a neuropeptide preparation mimicking the effects of neurotrophic factors. This subgroup analysis assessed safety and efficacy of Cerebrolysin in patients with moderate to moderately severe Alzheimer’s disease (AD) (ITT data set: N = 133; MMSE: 14–20) included in a dose‐finding study (ITT data set: N = 251; MMSE: 14–25). Results of the […]
Randomized controlled trial of a Healthy Brain Ageing Cognitive Training program: Effects on memory, mood, and sleep
Diamond, Keri,
Mowszowski, Loren,
Cockayne, Nicole,
Norrie, Louisa,
Paradise, Matthew,
Hermens, Daniel F.,
Lewis, Simon J. G.,
Hickie, Ian B.,
Naismith, Sharon L.
Background: With the rise in the ageing population and absence of a cure for dementia, cost-effective prevention strategies for those ‘at risk’ of dementia including those with depression and/or mild cognitive impairment are urgently required. Objective: This study evaluated the efficacy of a multifaceted Healthy Brain Ageing Cognitive Training (HBA-CT) program for older adults ‘at […]
Treatment with Huperzine A improves cognition in vascular dementia patients
Xu, Zhi-Qiang,
Liang, Xiao-Min,
Juan, Wu,
Zhang, Yuan-Feng,
Zhu, Chun-Xia,
Jiang, Xiao-Jiang
Unlabelled: In the present study, we tested the efficacy and safety of Huperzine A in treatment of mild to moderate vascular dementia (VaD). This was a randomized, double-blinded, placebo-controlled study with 78 patients with mild to moderate VaD. The participants were randomized to receive either vitamin C (100-mg bid) as placebo (n = 39) or […]
FMRI connectivity analysis of acupuncture effects on the whole brain network in mild cognitive impairment patients
Feng, Yuanyuan,
Bai, Lijun,
Ren, Yanshuang,
Chen, Shangjie,
Wang, Hu,
Zhang, Wensheng,
Tian, Jie
The increased risk for the elderly with mild cognitive impairment (MCI) to progress to Alzheimer’s disease makes it an appropriate condition for investigation. While the use of acupuncture as a complementary therapeutic method for treating MCI is popular in certain parts of the world, the underlying mechanism is still elusive. We sought to investigate the […]
Comparison of pharmacokinetics, pharmacodynamics, safety, and tolerability of the amyloid β monoclonal antibody solanezumab in Japanese and white patients with mild to moderate alzheimer disease
Uenaka, Kazunori,
Nakano, Masako,
Willis, Brian A.,
Friedrich, Stuart,
Ferguson-Sells, Lisa,
Dean, Robert A.,
Ieiri, Ichiro,
Siemers, Eric R.
Objectives: Solanezumab is a humanized anti-amyloid β monoclonal antibody being developed as a passive immunization treatment to slow the progression of Alzheimer disease (AD). Pharmacokinetics (PK), pharmacodynamics, safety, and tolerability after a single dose of solanezumab were compared between Japanese and white patients with AD.; Methods: Japanese and white patients with mild to moderate AD […]